The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients

Clinical Trial ID NCT03286712

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors.	JAMA	2005	5.46
2	The oxyhemoglobin reaction of nitric oxide.	Proc Natl Acad Sci U S A	1999	1.99
3	Immunologic function and survival in hemodialysis patients.	Kidney Int	1998	1.82
4	Inflammation in end-stage renal failure: could it be treated?	Nephrol Dial Transplant	2002	1.48
5	Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients.	Am J Kidney Dis	1995	1.41
6	Trends in anemia at initiation of dialysis in the United States.	Kidney Int	2001	1.19
7	In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease.	Hypertension	2007	1.12
8	Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.	Am J Kidney Dis	2002	1.03
9	Monitoring of inflammation in patients on dialysis: forewarned is forearmed.	Nat Rev Nephrol	2011	1.03
10	Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress.	Nephrol Dial Transplant	2002	0.97
11	Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease.	Kidney Int	2009	0.82